Abstract: Compounds and pharmaceutical compositions comprising a derivative of sulfuretin are provided that are inhibitors of the endoplasmic reticulum oxidoreductin-1 alpha. A method of treating a patient having cancer comprising administering to the patient a therapeutically effective amount of a compound that is a derivative of sulfuretin that are inhibitors of the endoplasmic reticulum oxidoreductin-1 alpha to a patient is disclosed.

Abstract: A method of inhibiting the development of osteoclasts in patients having multiple myeloma comprising administering to a patient having multiple myeloma a therapeutically effective amount of N-Methyl-dichloropropionaniline (i.e. also known as ELP-004) for inhibiting the development of osteoclasts. The method includes wherein said N-Methyl-dichloropropionaniline is administered to said patient in a pharmaceutically acceptable vehicle.

Abstract: A method of restoring the balance of osteoclast to osteoblast activity in a patient having rheumatoid arthritis comprising administering to a patient a therapeutically effective amount of the compound N-(3,4-dichlorophenyl)-N-methylpropanamide is provided. A method for treating arthritis-induced bone erosion in a patient comprising administering to a patient a therapeutically effective amount of the compound N-(3,4-dichlorophenyl)-N-methylpropanamide is provided. The compound N-(3,4-dichlorophenyl)-N-methylpropanamide is administered in a pharmaceutically acceptable composition to said patient. A mode of action of N-(3,4-dichlorophenyl)-N-methyl propanamide comprising targeting transient receptor potential channels is provided.

Abstract: The present invention relates to a methods for extending the period of filtering bleb survival and/or providing for long term bleb survival following Glaucoma Filtration Surgery by delivering an ALK-5 inhibitor to a wound area (the surgical site) of a patient's eye. More particularly, the present invention relates to a method for the controlled delivery of an ALK-5 inhibitor to patient's eye using a thermo-sensitive polymer formulation, wherein the ALK-5 inhibitor is first contained in the polymer formulation at a temperature sufficient to maintain the formulation as a liquid and then applied to the eye wound opening, wherein the formulation turns to a gel. The use of the thermo-sensitive gel with ALK-5 inhibitor contained therein, provides for longer term bleb survival following Glaucoma Filtration Surgery (GFS) on a patient's eye. Thus, the present invention is particularly effective in inhibiting ocular fibrotic wound response following GFS.